Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCL1 | Q07820 | 1/20 | 0.58 |
| ▸ | ERN1 | O75460 | 7/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | PRKDC | P78527 | 2/20 | 0.46 |
| ▸ | TLR2 | O60603 | 1/20 | 0.43 |
| ▸ | TLR1 | Q15399 | 1/20 | 0.43 |
| ▸ | TLR6 | Q9Y2C9 | 1/20 | 0.43 |
| ▸ | CA1 | P00915 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31346762 | 1.00 | MCL1 (0.58) | MCL1ERN1ALDH1A1KDM4ETSHR | |
| SCHEMBL1002837 | 0.86 | MCL1 (0.68) | MCL1ERN1ALDH1A1KDM4ETSHR | |
| SCHEMBL30855494 | 0.85 | MCL1 (0.72) | MCL1ERN1ALDH1A1KDM4ETSHR | |
| SCHEMBL18517642 | 0.85 | MCL1 (0.72) | MCL1ERN1ALDH1A1KDM4ETSHR | |
| SCHEMBL13080199 | 0.83 | MCL1 (0.45) | MCL1ERN1ALDH1A1KDM4EMAPK1 | |
| SCHEMBL13894553 | 0.82 | ALDH1A1 (0.50) | MCL1ERN1ALDH1A1KDM4ETSHR | |
| SCHEMBL8563051 | 0.82 | ALDH1A1 (0.48) | MCL1ERN1ALDH1A1KDM4EMAPK1 | |
| SCHEMBL5950414 | 0.82 | ALDH1A1 (0.50) | MCL1ERN1ALDH1A1KDM4ETSHR | |
| SCHEMBL485541 | 0.82 | MCL1 (0.58) | MCL1ERN1ALDH1A1KDM4ETSHR | |
| SCHEMBL25254136 | 0.81 | PRKDC (0.53) | MCL1ERN1ALDH1A1KDM4ETSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 76 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115813893-A | Application of naphthyl skeleton compound in preparing coronavirus 3CL protease inhibitor | 陕西科技大学 | 2023-03-21 | — | — | CN | claimed |
| CN-115813893-A | Application of naphthyl skeleton compound in preparing coronavirus 3CL protease inhibitor | 陕西科技大学 | 2023-03-21 | — | — | CN | disclosed |
| US-11091452-B2 | Polymerizable compound, polymerizable composition, polymer, optically anisotropic body, and method for producing polymerizable compound | ZEON CORPORATION (JP) | 2021-08-17 | — | — | US | disclosed |
| US-20200283399-A1 | METHOD OF PRODUCING POLYMERIZABLE COMPOUND, AND SOLUTION OF POLYMERIZABLE COMPOUND | ZEON CORPORATION (JP) | 2020-09-10 | — | — | US | disclosed |
| CN-106146338-B | Naphthaquinone derivative containing adamantyl, preparation method and application thereof | 中国科学院上海药物研究所 | 2020-09-08 | — | — | CN | disclosed |
| US-20200048213-A1 | POLYMERIZABLE COMPOUND, POLYMERIZABLE COMPOSITION, POLYMER, OPTICALLY ANISOTROPIC BODY, AND METHOD FOR PRODUCING POLYMERIZABLE COMPOUND | ZEON CORPORATION (JP) | 2020-02-13 | — | — | US | disclosed |
| EP-3604289-A1 | POLYMERIZABLE COMPOUND PRODUCTION METHOD AND POLYMERIZABLE COMPOUND SOLUTION | Zeon Corporation (JP) | 2020-02-05 | — | — | EP | disclosed |
| US-10173992-B2 | Polymerizable compound, polymerizable composition, polymer, optically anisotropic body, and method for producing polymerizable compound | ZEON CORPORATION (JP) | 2019-01-08 | — | — | US | disclosed |
| EP-2871192-B1 | POLYMERIZABLE COMPOUND, POLYMERIZABLE COMPOSITION, POLYMER, OPTICALLY ANISOTROPIC BODY, AND METHOD FOR PRODUCING POLYMERIZABLE COMPOUND | ZEON CORP (JP) | 2018-06-20 | — | — | EP | disclosed |
| EP-2203161-B1 | QUINONE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | UNIV INDIANA RES & TECH CORP (US) | 2018-05-09 | — | — | EP | disclosed |
| EP-0757629-B1 | IMAGING MEDIUM AND PROCESS | POLAROID CORP (US) | 1999-01-20 | — | — | EP | disclosed |
| EP-0549366-B1 | Thiazolidine compounds containing a quinone group, their preparation and their therapeutic uses | SANKYO CO (JP) | 1998-04-15 | — | — | EP | disclosed |
| US-5631118-A | MULTILAYER ELEMENT WITH ACID GENERATING LAYER, ACID PRECURSOR, SENSITIZING DYE, ACID GENERATOR AND COLOR CHANGING LAYER | POLAROID CORPORATION (US) | 1997-05-20 | — | — | US | disclosed |
| EP-0757629-A1 | IMAGING MEDIUM AND PROCESS | POLAROID CORPORATION (US) | 1997-02-12 | — | — | EP | disclosed |
| WO-1995029068-A1 | IMAGING MEDIUM AND PROCESS | POLAROID CORPORATION (US) | 1995-11-02 | — | — | WO | disclosed |
| US-5441850-A | Exposing medium to actinic radiation in specified wavelength so sensitizing dye decomposes superacid precursor, heating to decompose secondary acid generator, mixing acid generating and color change layers to form image, providing base to restore | POLAROID CORPORATION (US) | 1995-08-15 | — | — | US | disclosed |
| EP-0549365-B1 | Thiazolidine compounds, their preparation and their therapeutic uses | SANKYO CO (JP) | 1995-08-09 | — | — | EP | disclosed |
| US-5338855-A | Treating diabetes or hyperlipemia | SANKYO COMPANY, LIMITED (JP) | 1994-08-16 | — | — | US | disclosed |
| EP-0549366-A1 | Thiazolidine compounds containing a quinone group, their preparation and their therapeutic uses | Sankyo Company Limited (JP) | 1993-06-30 | — | — | EP | disclosed |
| EP-0549365-A1 | Thiazolidine compounds, their preparation and their therapeutic uses | Sankyo Company Limited (JP) | 1993-06-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10173992-B2 | Polymerizable compound, polymerizable composition, polymer, optically anisotropic body, and method for producing polymerizable compound | PYM1, C5, C1S | MCL1 2664/4885ERN1 3193/4885ALDH1A1 987/4885 |
| US-20200048213-A1 | POLYMERIZABLE COMPOUND, POLYMERIZABLE COMPOSITION, POLYMER, OPTICALLY ANISOTROPIC BODY, AND METHOD FOR PRODUCING POLYMERIZABLE COMPOUND | PDE8A, MAPT, PLK4 | MCL1 4198/4885ERN1 1196/4885ALDH1A1 3468/4885 |
| US-11091452-B2 | Polymerizable compound, polymerizable composition, polymer, optically anisotropic body, and method for producing polymerizable compound | PDE8A, MAPT, PLK4 | MCL1 4198/4885ERN1 1196/4885ALDH1A1 3468/4885 |
| US-20200283399-A1 | METHOD OF PRODUCING POLYMERIZABLE COMPOUND, AND SOLUTION OF POLYMERIZABLE COMPOUND | PDE8A, ADCY6, TKFC | MCL1 3032/4885ERN1 1631/4885ALDH1A1 2498/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.